🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A wonderful and important training, for which I'm very grateful to IASLC ! I highly recommend it 😁💪 Francesco Cortiula Laura Moliner Pedro Rocha Alessandro Di Federico

📊 An International EORTC Survey on Stage III NSCLC resectability: ✅ Resectable: Smaller tumors, w/ single-station N2 Larger tumours, w/ max N1 ❌ Unresectable: Bulky/invasive N2, N3 T4 tumours, w/ multi-station N2 Results shaped a consensual definition: lungcancerjournal.info/article/S0169-…

Just out in EJC the first case in Europe of advanced papillary thyroid cancer treated with first line alectinib. A useful experience for a rare disease with limited systemic treatment options. ejcancer.com/article/S0959-…

Some patients with oligometastatic NSCLC do benefit from radical therapy, but the majority doesn’t and has only a risk of treatment related tox. Biomarkers urgently needed. Read our review in JTO & JTO CRR jtocrr.org/article/S2666-… thanks to all collaborators

With ADCs bringing cytotoxic payloads, good to get a reminder in these basics, to understand toxicities

Ph I/II GDFATHER trial anti-GDF-15 visugromab+/-Nivo ⁦⁦⁦nature⁩ - 27pts w NSCLC - ORR 19.5% nonsq - 4CRs in NSCLC, UC, HCC With activity in IO resistance & cancer cachexia, is anti-GDF-15 the godfather of agents? ⁦OncoAlert⁩ #LCSM nature.com/articles/s4158…

🚀 Phase 1 mRNA based #immunotherapy Nature Medicine 🔹 Autogene cevumeran: individualized neoantigen-sp mRNA immunotherapy 🔹 36% Grade 3 AEs, CRS ‼️ 🔹T cell responses 71% 💥, durable: up to 23 months ⏳ 🔹 ➕ atezolizumab shows promise! OncoAlert go.nature.com/3DKcxnS

Neoadj Ipi+Nivo v Chemo in NSCLC Journal of Clinical Oncology - 221pts, I+Nx3 v chemo - mEFS 54.8m v 20.9m, but curves cross violating prop hazards - 26% cancelled surgeries in I+N (mainly early POD) - But I+N had overall less distant relapse (2 v 13% CNS) OncoAlert #LCSM ascopubs.org/doi/10.1200/JC…

The landscape in mNSCLC Is constantly evolving🧑‍⚕️ Thanks ESMO - Eur. Oncology for this great tool💥

IO has changed ttx and outcome in adv 🫁.It’s time that Academic trials (PULSE Benjamin Besse )and international grants test IO de-escalation to ensure ➕ pts receive these drugs, ⬆️outcomes to more pts worldwide, while ⬇️financial tox.Thk all authors!👏🏻 ascopubs.org/doi/10.1200/JC…

📣 Just updated: ESMO Non-oncogene-addicted mNSCLC Living Guideline v1.2 👉Find new recommendations with links to ESMO-MCBS scores, easily accessible from desktop and mobile devices. #ESMOGuidelines 🔗 ow.ly/SBUf50ULMaI

🚨 ICB Retreatment in unresectable Stage III #lcsm: Who Benefits? 🔎 ✅ PFS ≥12m on durvalumab? ICB retreatment improved OS (22m vs. 9.8m with chemo, p=0.024). ❌ PFS <12m? No survival benefit with ICB vs. chemo—huge unmet need! 🧩❓post-durvalumab space! ejcancer.com/article/S0959-…

Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab - European Journal of Cancer ejcancer.com/article/S0959-…

🔥European Journal of Cancer🆙 ✅Efficacy of Immunotherapy retreatment vs Chemo in Unresectable NSCLC with Progression Post CRT and Durvalumab 🎯PFS/OS HR 0.67 (95%CI 0.49-0.91) / 0.61 (0.43-0.86). ICB might offer⤴️survival 👥Francesco Cortiula #LCSM OncoAlert ejcancer.com/article/S0959-…

Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25

We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks ➕promising than chemo+Amiv. Better 🧠 protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT? #ELCC25

Congrats to all the authors for this great collaborative effort🏆 ICI retreatment after durvalumab for relapsed stage III NSCLC should be offered to selected patients💥📢 These results also confirm our previous findings🎯 Lizza Hendriks Andrea R. Filippi ejcancer.com/article/S0959-…

In JTO & JTO CRR #BRAF-mutated #NSCLC: bit.ly/JTO_BRAF 📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows: ➖ Similar OS outcomes ➖ PD-L1 status & gender influence prognosis 🎯 Personalization > one-size-fits-all LungCancerRx 🫁💊 OncoDaily Oncology Brothers

Fascinating paper Nature Cancer on mechanisms of resistance to TIL in NSCLC: - serial multiomic analysis, 16pt TIL trial - subclonal neoAg lost at progression - LOH of pMHC in KRAS-specific Tcells at progression Ben Creelan, MD Moffitt Cancer Center OncoAlert #LCSM nature.com/articles/s4301…